ProCE Banner Activity


Renal Cell Carcinoma: Update on Clinical Data, Trials, and Guidance for Community Practice


Watch this on-demand webcast for an update and expert insight on current and emerging data covering treatment of renal cell carcinoma.

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurses: 0.75 Nursing contact hour

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: January 26, 2023

Expiration: January 25, 2024



Naomi B. Haas

Naomi B. Haas, MD

Division of Hematology/Oncology
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Eric Jonasch

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner



Exelixis, Inc.

Merck Sharp & Dohme Corp.

Target Audience

This interprofessional training program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with RCC.

Learning Objectives

  • Appraise clinical data on systemic treatment approaches for patients with operable advanced or metastatic RCC
  • Identify patients most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
  • Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
  • Apply guideline-directed therapeutic strategies to optimize the sequence of therapies to provide the best outcome to patients with RCC
  • Manage specific disease-related complications or adverse events associated with currently approved monotherapies and therapy combinations for advanced RCC
  • Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Naomi B. Haas, MD

Division of Hematology/Oncology
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Naomi B. Haas, MD: consultant: Aveo, Eisai, Merck, Roche/Genentech.

Eric Jonasch, MD

Assistant Professor, Genitourinary Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, Texas

Eric Jonasch, MD: consultant/advisor/speaker: Aravive, Aveo, Calithera, DAVA Oncology, Eisai, Exelixis, Genentech, Ipsen, Merck, NiKang, Novartis, Takeda; researcher: Arrowhead, Merck, NiKang.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education
Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-039-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2023, through January 25, 2024:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.



The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for treatment of RCC.